Background The Eosinophilic fascitis (EF) is a uncommon sclerodermiforme síndrome with unknown etiology and poorly understood pathogenesis and natural evolution. The published series are short, with a total of 280 cases described in the literature from 1974.
There is neither clinical tests nor consensus on the EF treatment.
Objectives To describe a series of 21 patients with EF.
Methods Multicentric, retrospective Case Series Study.
We reviewed 21 patients diagnosed of EF (cutaneous induration+consistent biopsy) between January 1998 to January 2015. A total of 13 males and 8 females.
Results The mean age at diagnosis was 41 years 8range between 28 and 66).
Trigger factor was suspected in 8 patients (intense exercise in 7).
The zones of cutaneous affectation were fundamentally the upper and low extremities.
The hyperesonophilia was present in 100% of the patients. The average of the % more high of hyperesosinophilia was 21.2% (range 4–45.4%).
11 patients presented artralgias and 5 patients presented arthritis (4 polyarticular/1 oligoarticular).
The MRI was used for diagnosis and/or follow-up in 8 patients, especially in the diagnosed ones in the last 5 years.
The average initial dose of prednisone was 40 mg/día, the average maximum dose of prednisone was 40 mg/dia and the mean steroid treatment duration was 22 months (range 9–47 months). Other immunomodulatory agents were: methotrexate 11, hydroxychloroquine 2, azatioprina 2 and D penicillamine 1.
5 years after follow-up, the evolution was the complete resolution in 13 patients and the partial improvement in 6.
Conclusions In our series, the EF prevails in males, in the decade of the 40 and in the majority one did not find trigger factor. There was presence of arthritis in a significant percentage of patients. In the last years the use of the RMN has been added to the diagnosis and to the follow-up. Though there are no clinical tests that support it the use of the metotrexato has been generalized as adjuvant treatment to the steroids.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.